Feedback / Questions
REC-3565 - Recursion Pharma
https://www.globenewswire.com/news-release/2025/04/08/3057532/0/en/Recursion-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Study-of-REC-3565-a-Selective-MALT1-Inhibitor-for-Relapsed-or-Refractory-B-cell-Lymphomas.html
Apr 8, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next